Recently, Giant Biogene announced that it has entered into a strategic cooperation agreement with Nordberg Medical. Leveraging its proprietary synthetic biology technology platform, the two parties will jointly advance the global development and commercialization of recombinant collagen in the medical aesthetics and biomedical fields. This collaboration marks a key milestone in Giant Biogene’s globalization strategy, achieved through an innovative model of “technology licensing plus ecosystem co-building.”
Under the agreement, Giant Biogene will grant Nordberg Medical the rights to develop, manufacture and commercialize its patented recombinant collagen products in global markets outside mainland China. These materials will be used to develop a range of tissue regeneration products for the medical aesthetics sector. Giant Biogene’s recombinant collagen is characterized by low immunogenicity and the absence of viral risks, and demonstrates superior performance in tissue regeneration applications within the medical aesthetics field.
Nordberg Medical is a well-known biotechnology and medical device company based in Sweden. It owns the flagship medical aesthetics brand JULÄINE of Sweden™, whose core offerings are next-generation collagen biostimulators. To date, Nordberg Medical’s products have received regulatory approval in 33 markets and the company has established a direct sales network spanning more than 20 countries.
“We are pleased to deepen our global collaboration with Nordberg Medical, an innovator in regenerative medical aesthetics,” said Liu Lin, Director of Registered Projects at Giant Biogene. “By combining Nordberg Medical’s global development and commercialization platform with Giant Biogene’s unique recombinant collagen technology, we will accelerate the delivery of higher-quality tissue health solutions to medical aesthetics practitioners and consumers worldwide, helping consumers achieve natural beauty.”
In terms of financial performance, Giant Biogene reported revenue of RMB 3.113 billion in the first half of this year, representing a year-on-year increase of 22.52%. Net profit attributable to shareholders reached RMB 1.182 billion, up 20.23% year on year.
